NCIC Clinical Trials Group

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Other: placebo
Drug: paclitaxel

First Posted Date: 2008-11-21

Last Posted Date: 2023-08-22

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 306

Registration Number: NCT00795340

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 16 locations

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: ridaforolimus
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2008-10-09

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 35

Registration Number: NCT00770185

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada

and more 8 locations

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

Completed

Conditions: Breast Cancer
Osteoporosis

First Posted Date: 2008-06-02

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 238

Registration Number: NCT00688246

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 15 locations

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Phase 3

Terminated

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Liver Cancer

Interventions: Drug: capecitabine
Drug: gemcitabine hydrochloride
Procedure: quality-of-life assessment

First Posted Date: 2008-04-15

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 19

Registration Number: NCT00658593

Locations: 🇨🇦
Cross Cancer Institute at University of Alberta, Edmonton, Alberta, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada

and more 5 locations

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: buserelin
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Procedure: neoadjuvant therapy
Procedure: quality-of-life assessment
Radiation: radiation therapy
Drug: Docetaxel

First Posted Date: 2008-04-02

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 48

Registration Number: NCT00651326

Locations: 🇨🇦
McGill University - Dept. Oncology, Montreal, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada

and more 10 locations

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: brivanib alaninate

First Posted Date: 2008-03-21

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 750

Registration Number: NCT00640471

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦
Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇨🇦
Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada

and more 34 locations

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2007-09-26

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 26

Registration Number: NCT00535353

Locations: 🇨🇦
Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: cytarabine

First Posted Date: 2007-08-15

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 21

Registration Number: NCT00516828

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦
McGill University - Dept. Oncology, Montreal, Quebec, Canada

and more 1 locations

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: recombinant human interleukin-21
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2007-08-09

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 40

Registration Number: NCT00514085

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada

and more 4 locations

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: HDAC inhibitor SB939
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique
Other: laboratory biomarker analysis
Other: liquid chromatography
Other: mass spectrometry
Other: pharmacological study

First Posted Date: 2007-07-19

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 39

Registration Number: NCT00504296

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy